Patents Examined by Mark Berch
  • Patent number: 8575182
    Abstract: Certain 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts of the general formula are provided wherein R6 and R9 are as defined in the specification. These 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts are useful in compositions for treating mammalian cells, and especially human skin cells, in order to ameliorate the adverse effects of aging, treat skin disease states, treat immunological responses resulting from or associated with inflammation, and the like.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: November 5, 2013
    Assignee: Institute of Experimental Botany, Academy of Sciences of the Czeck Republic
    Inventors: Lucie Szucova, Marek Zatloukal, Lukas Spichal, Jiri Voller, Karel Dolezal, Miroslav Strnad, Frank J. Massino
  • Patent number: 8476285
    Abstract: The invention relates to compounds of Formulae I-III: and therapeutic uses thereof, wherein A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group; B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group; R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, or halo; and L1, L2, are as defined herein.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: July 2, 2013
    Assignee: Myrexis, Inc.
    Inventors: Ashok C. Bajji, Se-Ho Kim, Benjamin Markovitz, Richard Trovato, Rajendra Tangallapally, Mark B. Anderson, Daniel Wettstein, Mark Shenderovich, John A. Vanecko
  • Patent number: 8470809
    Abstract: The present invention relates to novel polymorph of Ceftiofur sodium as a crystalline product. The present invention also provides a process for the preparation of novel polymorphs of crystalline Ceftiofur sodium of formula (I).
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: June 25, 2013
    Assignee: Orchid Chemicals & Pharmaceuticals Limited
    Inventors: Sureshkumar Kanagaraj, Sivakumar Balasubramanian, Senthilkumar Udayampalayam Palanisamy
  • Patent number: 8450477
    Abstract: A process for manufacturing a compound of Formula (I) which has cis-conformation and wherein R1 represents a 1-phenyl-C1-C4alkyl or 1-naphthyl-C1-C4alkyl group, wherein the phenyl or naphthyl moiety of R1 is unsubstituted or substituted with one or more C1-C4alkoxy groups and the carbon atoms in 2-, 3-, and/or 4-position of the alkyl part of R1 are, independently of the phenyl or naphthyl moiety of R1 and independently of one another, unsubstituted or substituted with C1-C4alkoxy and/or silyloxy or, preferably, are unsubstituted or substituted with one C1-C4alkoxy group and/or silyloxy group per carbon atom, and R2 represents a C1-C6alkyl group or an unsubstituted or substituted benzyl group, in which process a compound of Formula (II) wherein R3 represents a C1-C6alkyl group or an unsubstituted or substituted benzyl group, and R1 and R2 have the same meaning as in formula (I); is treated with a base at a temperature of 0° C.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: May 28, 2013
    Assignee: Basilea Pharmaceutica A.G.
    Inventors: Marc Muller, Xiaoping Wu, Lin Xu
  • Patent number: 8445476
    Abstract: Carbacephem ?-lactam antibiotics having the following chemical structures (I) and (II) are disclosed: including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar2, R1, R2 and R3 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: May 21, 2013
    Assignee: Achaogen, Inc.
    Inventors: Allan S. Wagman, Heinz E. Moser
  • Patent number: 8445673
    Abstract: The present invention relates to a process for the preparation of sterile doripenem.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: May 21, 2013
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Vinod George, Hashim Nizar Poovanathil Nagoor Meeran, Neera Tiwari, Mohan Prasad
  • Patent number: 8440819
    Abstract: A compound having a structure or a pharmaceutically acceptable salt thereof, or a prodrug thereof; wherein a dashed line represents the presence or absence of a bond; Y has from 0 to 14 carbon atoms and is: an organic acid functional group, or an amide or ester thereof; hydroxymethyl or an ether thereof; or a tetrazolyl functional group; A is —(CH2)6—, cis-CH2CH?CH—(CH2)3—, or —CH2C?C—(CH2)3—, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is —(CH2)m—Ar—(CH2)o— wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 -CH2— may be replaced by S or O, and 1 -CH2—CH2— may be replaced by —CH?CH— or —C?C—; J is hydrogen, OH, O, SH, S, C1-6 alkyl, —O—(C1-6 alkyl), —S—(C1-6 alkyl), F, Cl, Br, I, CN, or CF3; and B is aryl or heteroaryl, is disclosed herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: May 14, 2013
    Assignee: Allergan, Inc.
    Inventor: David W. Old
  • Patent number: 8440677
    Abstract: The invention provides compounds, compositions and methods to treat certain inflammatory conditions and/or oncology by administering a compound that inhibits PI3K isoforms, particularly the delta isoform. It further provides specific stereoisomers of a compound useful for these methods. In particular, the compound is an optically active atropisomer of 2-((6-amino-9H-purin-9-yl)methyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: May 14, 2013
    Assignee: Gilead Calistoga LLC
    Inventors: Jerry B. Evarts, Roger G. Ulrich
  • Patent number: 8440661
    Abstract: Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.
    Type: Grant
    Filed: May 13, 2010
    Date of Patent: May 14, 2013
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Brydon L. Bennett, Kate Northcote, Brian Edwin Cathers
  • Patent number: 8435969
    Abstract: A compound of formula 1 and/or its salts, tautomers or solvates is used to treat hematological malignancies. In an embodiment, an organic acid salt of compound 1 is provided for general use in treatment of neoplasms, and in a further embodiment the salt is stabilized with carbohydrate.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: May 7, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Adrian S. Ray, Daniel B. Tumas, Hans Reiser, William J. Watkins, William A. Lee, Lee S. Chong
  • Patent number: 8431562
    Abstract: Polymorphs of Ceftiofur sodium as a crystalline product and a process for the preparation of polymorphs of crystalline Ceftiofur sodium of formula (I).
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: April 30, 2013
    Assignee: Orchid Chemicals & Pharmaceuticals Limited
    Inventors: Senthilkumar Udayampalayam Palanisamy, Sivakumar Balasubramanian, Manimaran Arasappan, Meenakshi Sundaram Soma Sundaram, Sureshkumar Kanagaraj, Mohan Singaravel
  • Patent number: 8431583
    Abstract: At least one compound of following formula I: in which: X is C or N, Y is CH3 or OH, and Z is H or CH3, or one of its pharmaceutically acceptable salts, hydrates, esters or isomers, for use in the manufacture of a medicament to treat pathologies in which an imbalance between cell division and apoptosis is involved.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: April 30, 2013
    Assignees: Centre National de la Recherche Scientifique, Universite de Rennes 1, Universite Paris Descartes, Universite de Bretagne Occidentale, Centre Hospitalier Universitaire de Brest
    Inventors: Laurent Meijer, Karima Bettayeb, Hervé Galons, Nassima Oumata, Christian Berthou, Karine Lester
  • Patent number: 8426400
    Abstract: Substituted 2-(azetidin-2-on-1-yl)alkoxyalkylalkanoic acids and 2-(azetidin-2-on-1-yl)arylalkylalkanoic acids, and analogs and derivatives thereof are described. Methods for using the described compounds, and pharmaceutical compositions thereof, to treat disease states responsive to antagonism of one or more vasopressin receptors are also described.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: April 23, 2013
    Assignee: Azevan Pharmaceuticals, Inc.
    Inventors: Gary A. Koppel, Marvin J. Miller
  • Patent number: 8420806
    Abstract: The present invention relates to a process for the preparation of cefadroxil in crystal form, comprising a) adding an aqueous solution of cefadroxil to a crystallization vessel and a titrant to keep a pH in the crystallization vessel of between 7 to 9; and b) lowering the pH in the crystallization vessel to a value of between 5 and 6.5 to obtain a suspension of the ?-lactam compound in crystal form. The invention further relates to cefadroxil in crystal form obtainable by the process according to the present invention. The invention also relates to cefadroxil in crystal form with a CIE b value of below 12 when stored at a temperature of 25° C. for at least 1 month.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: April 16, 2013
    Assignee: DSM Sinochem Pharmaceuticals Netherlands B.V.
    Inventors: Carlos Enrique Lenhard, Harold Monro Moody, Theodorus Johannes Godfried Maria Van Dooren
  • Patent number: 8420628
    Abstract: Disclosed herein is a compound comprising or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein Y is an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group; A is —(CH2)6—, cis —CH2CH?CH—(CH2)3—, or —CH2C?C—(CH2)3—, wherein 1 or 2 carbon atoms may be substituted with S or O; or A is —(CH2)m—Ar—(CH2)o— wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one CH2 may be substituted with S or O; and D is aryl or heteroaryl.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: April 16, 2013
    Assignee: Allergan, Inc.
    Inventor: David W. Old
  • Patent number: 8420813
    Abstract: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents. Also provided are processes for the preparation of the compounds and their intermediates such as: wherein: R2 and R21 are defined in the description.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: April 16, 2013
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Guoquan Wang, Jayson M Rieger, Robert Thompson
  • Patent number: 8404671
    Abstract: The invention relates to heterosubstituted N-thiolated beta-lactams, compositions comprising these compounds, methods for their production, and methods of use as antibiotics to inhibit the growth of bacteria. In one embodiment, the compounds have the structure shown in formula (A) or formula (B) or formula (C): wherein the R groups are as defined in the specification. The antibacterial agents of the invention can be administered to a human or animal to treat or inhibit bacterial infection, such as that of Staphylococcus species, including methicillin-resistant Staphylococcus aureus (MRSA).
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: March 26, 2013
    Assignee: University of South Florida
    Inventors: Edward Turos, Praveen Ramaraju
  • Patent number: 8404674
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1, R2 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Grant
    Filed: March 4, 2008
    Date of Patent: March 26, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Heinz Stadtmueller, Guido Boehmelt, Harald Engelhardt, Ulrich Hirt, Otmar Schaaf, Irene Waizenegger
  • Patent number: 8394808
    Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: March 12, 2013
    Assignee: Glaxosmithkline LLC
    Inventors: Ivan Leo Pinto, Shahzad Sharooq Rahman, Neville Hubert Nicholson
  • Patent number: 8389722
    Abstract: Adefovir Dipivoxil monohydrate crystalline is disclosed.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: March 5, 2013
    Assignee: Fidia Farmaceutici S.p.A.
    Inventors: Stefania Galimi, Emilio Vecchio, Roberta Pizzocaro